Michael Barbella, Managing Editor10.03.23
Allurion Technologies Inc. has added two new executives to its top management team. Douglas Hudson has joined the company's Board of Directors and Tomer Stavitsky is now vice president of Corporate Development.
"We are excited to welcome both Doug and Tomer to Allurion," Allurion Founder/CEO Dr. Shantanu Gaur said. "Doug is an exceptional entrepreneur with deep experience in the consumerization of healthcare and digital products as both an operator and board member. Tomer brings a wealth of experience in healthcare M&A, partnerships and investments, and joins Allurion as we accelerate the expansion of our weight loss AI platform."
Hudson most recently founded Tend, where he has successfully leveraged his past experiences to reimagine the dental industry with a hospitality mindset. Previously, he founded and led various successful consumer-facing ventures, including the founding CEO of SmileDirectClub and chairman/CEO of DiabetesCareClub, CPAPCareClub and HearingPlanet, the latter of which became the largest online hearing aid distributor in the United States during his tenure.
“I am thrilled to join Allurion at a pivotal moment as it goes public and expands its reach to consumers all over the world,” Hudson stated. “I am looking forward to working with my fellow board members and the company’s management to set a new standard for a best-in-class weight loss experience.”
As Allurion's vice president of Corporate Development, Stavitsky is focused on M&A and partnership strategy, particularly in AI and digital health. Previously, Stavitsky led M&A at Ginkgo Bioworks, and Corporate Development for the Digital & Data Business Unit at Intuitive Surgical. At Intuitive Surgical, Stavitsky evaluated hundreds of deals spanning AI and machine learning, digital health, telehealth and data analytics, and executed several key deals, including the acquisition of Orpheus Medical, which led to the establishment of Intuitive Surgical’s AI development center in Israel.
Allurion went public in early August pursuant to a business combination with Compute Health. It is listed on the New York Stock Exchange under the ticker symbol “ALUR.”
The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. Allurion is a trademark of Allurion Technologies Inc. in the United States and countries worldwide.
Compute Health is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Compute Health is led by the management team of Omar Ishrak, Jean Nehmé and Joshua Fink. Compute Health’s strategy is to focus on healthcare businesses that are already leveraging or have the potential to leverage computational power, with an emphasis on companies in the medical device space, including imaging and robotics.
"We are excited to welcome both Doug and Tomer to Allurion," Allurion Founder/CEO Dr. Shantanu Gaur said. "Doug is an exceptional entrepreneur with deep experience in the consumerization of healthcare and digital products as both an operator and board member. Tomer brings a wealth of experience in healthcare M&A, partnerships and investments, and joins Allurion as we accelerate the expansion of our weight loss AI platform."
Hudson most recently founded Tend, where he has successfully leveraged his past experiences to reimagine the dental industry with a hospitality mindset. Previously, he founded and led various successful consumer-facing ventures, including the founding CEO of SmileDirectClub and chairman/CEO of DiabetesCareClub, CPAPCareClub and HearingPlanet, the latter of which became the largest online hearing aid distributor in the United States during his tenure.
“I am thrilled to join Allurion at a pivotal moment as it goes public and expands its reach to consumers all over the world,” Hudson stated. “I am looking forward to working with my fellow board members and the company’s management to set a new standard for a best-in-class weight loss experience.”
As Allurion's vice president of Corporate Development, Stavitsky is focused on M&A and partnership strategy, particularly in AI and digital health. Previously, Stavitsky led M&A at Ginkgo Bioworks, and Corporate Development for the Digital & Data Business Unit at Intuitive Surgical. At Intuitive Surgical, Stavitsky evaluated hundreds of deals spanning AI and machine learning, digital health, telehealth and data analytics, and executed several key deals, including the acquisition of Orpheus Medical, which led to the establishment of Intuitive Surgical’s AI development center in Israel.
Allurion went public in early August pursuant to a business combination with Compute Health. It is listed on the New York Stock Exchange under the ticker symbol “ALUR.”
The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. Allurion is a trademark of Allurion Technologies Inc. in the United States and countries worldwide.
Compute Health is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Compute Health is led by the management team of Omar Ishrak, Jean Nehmé and Joshua Fink. Compute Health’s strategy is to focus on healthcare businesses that are already leveraging or have the potential to leverage computational power, with an emphasis on companies in the medical device space, including imaging and robotics.
